Conferences - Results from #160

Viewing 161-180 of 11487 articles

ASCO 2024: Quantitative Circulating Tumor DNA (ctDNA) Assessment in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab or Platinum-Based Chemotherapy from the Phase 3 KEYNOTE-361 Trial

ASCO 2024: Integration of Functional Imaging in Renal Cell Carcinoma

ASCO 2024: Baseline ctDNA Analyses and Associations with Outcomes in Taxane-Naive Patients with mCRPC Treated with 177Lu-PSMA-617 Versus Change of ARPI in PSMAfore

ASCO 2024: MANCAN2: A Multicenter Randomized Controlled Trial of Self-Help Cognitive Behavioral Therapy to Manage Hot Flush and Night Sweat Symptoms in Patients with Prostate Cancer Receiving ADT

ASCO 2024: Perioperative Sacituzumab Govitecan Alone or in Combination with Pembrolizumab for Patients with Muscle-invasive Urothelial Bladder Cancer: SURE-01/02 Interim Results

ASCO 2024: CYCLONE 2: A Phase 3 study of Abemaciclib with Abiraterone in Patients with mCRPC

ASCO 2024: Perioperative Sacituzumab Govitecan Alone or in Combination with Pembrolizumab for Patients with Muscle-Invasive Urothelial Bladder Cancer: SURE-01/02 Interim Results

ASCO 2024: Cabazitaxel with Abiraterone versus Abiraterone Alone - Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial of the ECOG-ACRIN Cancer Research Group (EA8153)

ASCO 2024: PSMAfore: HRQoL and Pain in a Phase 3 Study of 177Lu-PSMA-617 in Taxane-Naïve Patients with mCRPC

ASCO 2024: The MAST (Metformin Active Surveillance Trial) Study: A Randomized, Double-blind, Placebo-controlled Trial of Metformin for Reducing Progression Among Men on Expectant Management for Low-risk Prostate Cancer

ASCO 2024: Avelumab as Neoadjuvant Therapy in Patients with Muscle-Invasive Urothelial Carcinoma: Survival Data of AURA Trial, Oncodistinct 004

ASCO 2024: Systemic Treatments in Favorable and Very Favorable Risk Metastatic Renal Cell Carcinoma (mRCC): Real World Evidence from the International mRCC Database Consortium (IMDC).

ASCO 2024: Investigation of T Cell Phenotypes Associated with Response or Resistance to Immune Checkpoint Inhibitors (ICI) Through Single-Cell Analysis of Renal Cell Carcinoma (RCC)

ASCO 2024: Advanced Sequencing and Targeted Therapy Strategies in Renal Cell Carcinoma: How Can We Help More Patients Not at the Expense of Toxicity?

ASCO 2024: Preliminary Safety, Pharmacokinetics and Clinical Activity of DFF332, an Oral HIF2α Inhibitor, as Monotherapy in a Phase 1 Dose Escalation Study in Patients with Advanced Clear Cell Renal Cell Carcinoma.

ASCO 2024: A Multi-Institution Analysis of Outcomes With First-Line Systemic Therapy for 102 Patients With Metastatic Chromophobe Renal Cell Carcinoma

ASCO 2024: Camrelizumab plus Apatinib for Previously Treated Advanced Adrenocortical Carcinoma: A Single-Arm, Open-Label, Phase 2 Trial.

ASCO 2024: Using Molecular Testing to Guide Perioperative Systemic Therapy for Urothelial Cancer

ASCO 2024: A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTMA; KCSG GU20-03)

ASCO 2024: Optimal Treatment Intensity for Frontline Therapy for Advanced Urothelial Cancer: Which Regimen for Which Patient?

4
5
6
7
8
9
10
11
12
13